Company
Dr. Reddy's Laboratories Limited
Headquarters: Hyderabad, India
Founded: 1984
Employees: 22,739
CEO: Mr. Erez Israeli M.B.A.
Market Cap
$11.86 Billion
USD as of Jan. 1, 2024
Dr. Reddy's Laboratories Limited Categories
India Healthcare Drug Manufacturers—Specialty & GenericIndia Healthcare India Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Dr. Reddy's Laboratories Limited has the following listings and related stock indices.
Stock: NYSE: RDY wb_incandescent
Product & Services
Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health
Key People
Founder(s): Kallam Anji Reddy
G. V. Prasad (Co-Chairman & M D) Kallam Satish Reddy (Chairman) Erez Israeli (CEO)
Financials
Revenue: ₹17,460 crore (US$2.3 billion) (2020)
Operating income: ₹1,599 crore (US$210 million) (2020)
Net income: ₹1,950 crore (US$260 million) (2020)
Total assets: ₹23,156 crore (US$3.0 billion) (2020)
Total equity: ₹15,499 crore (US$2.0 billion) (2020)